Sign In
Buy LPCN
$2.19
-0.0600 (-2.67%)
At Close: Jun 03, 2026
Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission
11:59am, Monday, 24'th Feb 2020
Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with the U.S. Food and Drug Admini
Lipcine Says the FDA is Satisfied with its Approach to Collect Data for the Resubmission of TLANDO
12:00am, Monday, 24'th Feb 2020Lipocine Receives Patent Titled 'Testosterone undecanoate compositions'
12:00am, Wednesday, 19'th Feb 2020Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics
09:26pm, Tuesday, 11'th Feb 2020
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in its infringement lawsuit agains
Lipocine 13G Filing From Hudson Bay Capital Shows 9.99% Stake
12:00am, Thursday, 06'th Feb 202020 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session
12:00am, Monday, 27'th Jan 202014 Drug Manufacturers—Specialty & Generic Stocks Moving In Thursday's Session
12:00am, Thursday, 23'rd Jan 202018 Drug Manufacturers—Specialty & Generic Stocks Moving In Wednesday's Session
12:00am, Wednesday, 22'nd Jan 2020
TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc.
LOS ANGELES, CA / ACCESSWIRE / January 14, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Lipocine Inc. ("Lipocine"
NEW YORK, Jan. 14, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Lipocine Inc. (NASDAQ: LPCN) between March 27, 2019 and.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on
